A UK antifungal player with a Big Pharma pedigree bags fresh round of cash as it races toward late-stage trial
The London-based biotech Pulmocide has been pushing its inhaled antifungal toward the clinic for a while now, and early Thursday morning received a new heaping of cash to get it into a Phase III study.
Pulmocide pulled in a $92 million Series C round, the company announced, and will funnel the money toward its PC945 program. The biotech is shooting for patients with invasive pulmonary aspergillosis — a lung infection generally seen in immunosuppressed patients or those with recent transplants — who have failed all other therapies, with the goal to start recruiting for Phase III by the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
